Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Capacity shortage
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Lund University | OTHER |
Not provided
Not provided
Not provided
Not provided
The medium cut-off dialysis (MCO) membrane has been developed to improve middle molecule removal compared to standard high-flux dialysis filters.
The aim of this study is to compare levels of middle molecules after 12 weeks of MCO hemodialysis, compared to 12 weeks of hemodiafiltration using standard high-flux filter.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MCO-HD | Experimental | Hemodialysis with Medium Cut-Off filter |
|
| High-flux HDF | Active Comparator | Hemodiafiltration with standard high-flux filter |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MCO-HD | Device | Measurements will be done after 0,4,8 and 12 weeks of hemodialysis with Medium Cut-Off filter. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Comparison of predialysis mean of middle molecules after 12 weeks (Beta-2-microglobulin, Cystatin C, Myoglobin, Beta-Trace Protein, Troponin T, Prealbumin). | 12 weeks | |
| Comparison of postdialysis mean of middle molecules after 12 weeks (Beta-2-microglobulin, Cystatin C, Myoglobin, Beta-Trace Protein, Troponin T, Prealbumin). | 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Comparison of predialysis mean of small molecules (CRP, Urea, Phosphate and Creatinine) after 12 weeks. | 12 weeks | |
| Comparison of postdialysis mean of of small molecules (CRP, Urea, Phosphate and Creatinine) after 12 weeks. | 12 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
- Not able to understand the study information.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Anders Christensson, MD, PhD | Region Skane, Lund University | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D051436 | Renal Insufficiency, Chronic |
| D014511 | Uremia |
| ID | Term |
|---|---|
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| high-flux HDF | Device | Measurements will be done after 0,4,8 and 12 weeks of hemodiafiltration with standard high-flux filter |
|
| Comparison of predialysis mean of large molecules after 12 weeks (Albumin, Transferrin, IgG). | 12 weeks |
| Comparison of postdialysis mean of large molecules after 12 weeks (Albumin, Transferrin, IgG). | 12 weeks |
| Comparison of pre- and postdialysis mean of all molecules at 0, 4 and 8 weeks. | 8 weeks |
| Comparison of number of adverse effects during the study period. | 12 weeks |
| Comparison of mean nPCR after 12 weeks. | 12 weeks |
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |